LEADER 02297nam 2200361 450 001 9910598175303321 005 20230219152212.0 035 $a(CKB)4920000000095109 035 $a(NjHacI)994920000000095109 035 $a(EXLCZ)994920000000095109 100 $a20230219d2018 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aCurrent aspects of radiopharmaceutical chemistry /$fedited by Peter Brust 210 1$a[Place of publication not identified] :$cMDPI - Multidisciplinary Digital Publishing Institute,$d2018. 215 $a1 online resource (216 pages) 311 $a3-03897-162-6 330 $aPositron emission tomography (PET) and single-photon emission computed tomography (SPECT) are in vivo molecular imaging techniques which are widely used in nuclear medicine for the diagnosis and treatment follow-up of many major diseases. They use biomolecules as probes, which are labeled with radionuclides of short half-lives, synthesized prior to the imaging studies. These probes are called radiopharmaceuticals. Their design and development require a rather interdisciplinary process involving many different disciplines of natural and health sciences. In addition to their diagnostic and therapeutic purposes in the field of nuclear medicine, radiopharmaceuticals provide powerful tools for in vivo pharmacology during the process of pre-clinical drug development to identify new drug targets, investigate the pathophysiology of diseases, discover potential drug candidates, and evaluate the pharmacokinetics and pharmacodynamics of drugs in vivo. Furthermore, they allow molecular imaging studies in various small-animal models of disease, including genetically engineered animals. The current collection of articles provides unique examples covering all major aspects in the field. 606 $aRadiopharmaceuticals 606 $aDrug delivery systems 615 0$aRadiopharmaceuticals. 615 0$aDrug delivery systems. 676 $a616.07575 702 $aBrust$b Peter 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910598175303321 996 $aCurrent Aspects of Radiopharmaceutical Chemistry$92948905 997 $aUNINA